MRKR is trading 5.2% up at $1.38 as biotech names benefit from a stronger risk-on session and higher U.S. indexes.
- No confirmed company-specific news, earnings, or FDA updates have been reported to account for the move.
- The price action appears to be tracking the broader market tone rather than a specific Marker Therapeutics catalyst.